Sunovion Re-Submits Approval Request for APL-130277 to FDA for Treating Parkinson’s Off Periods

Sunovion Re-Submits Approval Request for APL-130277 to FDA for Treating Parkinson’s Off Periods
Sunovion Pharmaceuticals has re-submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), once again seeking the approval of its below-the-tongue formulation of apomorphine — called APL-130277 — for Parkinson’s off periods. The re-submission is a follow-up to the FDA’s “complete response letter” from earlier this year, in which the agency requested additional information — but no ... read more
Source: Parkinson’s News TodayPublished on 2019-11-26By Patricia Inacio, PhD